Vemurafenib

Recent Results in Cancer Research

Volumn 201, Issue , 2014, Pages 215-225

  Garbe, Claus ^a   Abusaif, Sail ^a   Eigentler, Thomas K ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

BRAF inhibitor; BRAF mutation; Melanoma; Vemurafenib

Indexed keywords

B RAF KINASE; CAFFEINE; DACARBAZINE; DEXTROMETHORPHAN; LACTATE DEHYDROGENASE; MIDAZOLAM; MITOGEN ACTIVATED PROTEIN KINASE; OXIDOREDUCTASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN S100B; VEMURAFENIB; WARFARIN; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; SULFONAMIDE;

ACUTE KIDNEY FAILURE; ALOPECIA; ANTIPROLIFERATIVE ACTIVITY; ARTHRALGIA; ARTICLE; BINDING AFFINITY; BRAF GENE; CANCER PROGNOSIS; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; COLORECTAL CANCER; COMPARATIVE EFFECTIVENESS; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG RESISTANCE; DRUG RESPONSE; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FACIAL NERVE PARALYSIS; FATIGUE; GENE IDENTIFICATION; GENE MUTATION; HAIRY CELL LEUKEMIA; HAND FOOT SYNDROME; HUMAN; HYPERTRANSAMINASEMIA; KERATOACONTHOMA; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER METASTASIS; MAXIMUM PLASMA CONCENTRATION; METASTATIC MELANOMA; MOLECULARLY TARGETED THERAPY; MULTICENTER STUDY (TOPIC); NAUSEA; NON SMALL CELL LUNG CANCER; NONHUMAN; OVERALL SURVIVAL; PAPILLARY THYROID CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOTOSENSITIVITY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; PRURITUS; QT PROLONGATION; RASH; RETINA VEIN OCCLUSION; SKIN CARCINOMA; SKIN PAPILLOMA; SKIN TUMOR; SURVIVAL TIME; THYROID CANCER; TIME TO MAXIMUM PLASMA CONCENTRATION; TUMOR GROWTH; TUMOR REGRESSION; TUMOR VOLUME; ANIMAL; GENETICS; MELANOMA; MUTATION; NEOPLASM; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; INDOLES; MELANOMA; MUTATION; NEOPLASMS; PROTO-ONCOGENE PROTEINS B-RAF; SULFONAMIDES;

EID: 84905123422     PISSN: 00800015     EISSN: 21976767     Source Type: Book Series    
DOI: 10.1007/978-3-642-54490-3_13     Document Type: Article

References (36)

1. Abusaif S, Jradi Z, Held L et al (2013) S100B and lactate dehydrogenase as response and progression markers during treatment with vemurafenib in patients with advanced melanoma. Melanoma Res 2013, Epub ahead of print.
2. Balch CM, Gershenwald JE, Soong SJ et al (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27: 6199-6206.
3. Bollag G, Hirth P, Tsai J et al (2010) Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467: 596-599.
4. Carlson JA, Ross JS, Slominski A et al (2005) Molecular diagnostics in melanoma. J Am Acad Dermatol 52: 743-775.
5. Chapman PB, Hauschild A, Robert C et al (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364: 2507-2516.
6. Chapman PB, Hauschild A, Robert C et al (2012) Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAFV600E-mutated melanoma. J Clin Oncol 30: 8502.
7. Davies H, Bignell GR, Cox C et al (2002) Mutations of the BRAF gene in human cancer. Nature 417: 949-954.
8. Dietrich S, Glimm H, Andrulis M, von Kalle C, Ho AD, Zenz T (2012) BRAF inhibition in refractory hairy-cell leukemia. N Engl J Med 366: 2038-2040.
9. Eigentler TK, Garbe C (2006) Malignant melanoma: classification and staging of malignant melanoma. Front Radiat Ther Oncol 39: 149-158.
10. European Medicines Agency (2013) Zelboraf-Annex I-Summary of product characteristics. 19 June 2013.
11. Finck SJ, Giuliano AE, Morton DL (1983) LDH and melanoma. Cancer 51: 840-843.
12. Flaherty KT, Puzanov I, Kim KB et al (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363: 809-819.
13. Gautschi O, Pauli C, Strobel K et al (2012) A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib. J Thorac Oncol 7: e23-e24.
14. Gogas H, Eggermont AM, Hauschild A et al (2009) Biomarkers in melanoma. Ann Oncol 20(6): vi8-vi13.
15. Greenman C, Stephens P, Smith R et al (2007) Patterns of somatic mutation in human cancer genomes. Nature 446: 153-158.
16. Hauschild A, Engel G, Brenner W et al (1999) S100B protein detection in serum is a significant prognostic factor in metastatic melanoma. Oncology 56: 338-344.
17. Hoffmann-La Roche Ltd (2012) Roche's Zelboraf receives EU approval for the treatment of people with deadly form of skin cancer. http://www. roche. com/media/media_releases/med-cor-2012-02-20. htm.
18. Kim KB, Cabanillas ME, Lazar AJ et al (2013) Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation. Thyroid 23: 1277-1283.
19. Kopetz S, Desai J, Chan E et al (2010) PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumours. J Clin Oncol 28: 3534.
20. Mao M, Tian F, Mariadason JM et al (2013) Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. Clin Cancer Res 19: 657-667.
21. Naoki K, Chen TH, Richards WG, Sugarbaker DJ, Meyerson M et al (2002) Missense mutations of the BRAF gene in human lung adenocarcinoma. Cancer Res 62: 7001-7003.
22. Oberholzer PA, Kee D, Dziunycz P et al (2012) RAS mutations are associated with the development of cutaneous squamous cell tumours in patients treated with RAF inhibitors. J Clin Oncol 30: 316-321.
23. Peyrade F, Re D, Ginet C et al (2013) Low-dose vemurafenib induces complete remission in a case of hairy-cell leukaemia with a V600E mutation. Haematologica 98: e20-e22.
24. Peyssonnaux C, Eychene A (2001) The Raf/MEK/ERK pathway: new concepts of activation. Biol Cell 93: 53-62.
25. Pflugfelder A, Eigentler TK, Keim U et al (2011) Effectiveness of carboplatin and paclitaxel as first-and second-line treatment in 61 patients with metastatic melanoma. PLoS One 6: e16882.
26. Prahallad A, Sun C, Huang S et al (2012) Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 483: 100-103.
27. Schreck R, Rapp UR (2006) Raf kinases: oncogenesis and drug discovery. Int J Cancer 119: 2261-2271.
28. Shah N, Iyer RM, Mair HJ et al (2013) Improved human bioavailability of vemurafenib, a practically insoluble drug, using an amorphous polymer-stabilized solid dispersion prepared by a solvent-controlled coprecipitation process. J Pharm Sci 102: 967-981.
29. Sirott MN, Bajorin DF, Wong GY et al (1993) Prognostic factors in patients with metastatic malignant melanoma: a multivariate analysis. Cancer 72: 3091-3098.
30. Sosman JA, Kim KB, Schuchter L et al (2012) Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 366: 707-714.
31. Tanaka H, Deng G, Matsuzaki K et al (2006) BRAF mutation, CpG island methylator phenotype and microsatellite instability occur more frequently and concordantly in mucinous than nonmucinous colorectal cancer. Int J Cancer 118: 2765-2771.
32. Tiacci E, Trifonov V, Schiavoni G et al (2011) BRAF mutations in hairy-cell leukemia. N Engl J Med 364: 2305-2315.
33. Tie J, Gibbs P, Lipton L et al (2011) Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF(V600E) mutation. Int J Cancer 128: 2075-2084.
34. U. S. Food and Drug Administration (2011) FDA approves Zelboraf and companion diagnostic test for late-stage skin cancer. http://www. roche. com/media/media_releases/med-cor-2012-02-20. htm.
35. Weide B, Elsasser M, Buttner P et al (2012) Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis. Br J Cancer 107: 422-428.
36. Xing M (2007) BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev 28: 742-762.